TECH Signal 435
People Get Paid for Blood, Plasma, and Drug Trials—Why Not Kidneys Too?
↗
Instead of kidney waitlists that kill thousands of people a year, let people get paid for kidney transplants.
The article argues that legalizing payment for kidney donation could eliminate the U.S. organ waitlist, which currently causes about 4,000 deaths annually. It draws parallels to compensated blood, plasma, and clinical trial participation, showing that bodily commodification already occurs in ways that benefit public health. The author contends that objections to paying kidney donors are inconsistent with societal acceptance of similar practices.
Written by elseif from the cluster below · every claim links back to a sourceThe three things worth knowing
The U.S. kidney waitlist causes about 4,000 deaths annually and requires many patients to endure years of dialysis.
Iran eliminated its kidney waitlist after legalizing payment to donors in 1988, demonstrating a functional model.
Compensation for bodily resources like blood, plasma, and clinical trial participation already exists and is widely accepted.
THE READ
What the cluster adds up to.
The article proposes paying kidney donors as a solution to the lethal organ shortage, contrasting it with the current system that relies on unpaid donations and results in preventable deaths.
Adopting payment would require overcoming ethical objections that the author dismisses as inconsistent, given society's acceptance of compensated blood, plasma, and clinical trial participation.
The proposal faces practical hurdles including regulatory barriers, public perception, and the need to design fair compensation structures that avoid exploitation.
Written by elseif from the cluster below · checked for specifics the sources never containedTHE CLUSTER